Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Gi‐Hoon NamBiomedical Research Institute Korea Institute of Science and Technology (KIST) Seoul 02792 Republic of KoreaYoonjeong ChoiBiomedical Research Institute Korea Institute of Science and Technology (KIST) Seoul 02792 Republic of KoreaGi Beom KimBiomedical Research Institute Korea Institute of Science and Technology (KIST) Seoul 02792 Republic of KoreaSeohyun KimBiomedical Research Institute Korea Institute of Science and Technology (KIST) Seoul 02792 Republic of KoreaSeong A KimBiomedical Research Institute Korea Institute of Science and Technology (KIST) Seoul 02792 Republic of KoreaIn‐San KimBiomedical Research Institute Korea Institute of Science and Technology (KIST) Seoul 02792 Republic of Korea
2020en
ABI

Аннотация

Exosomes are a class of extracellular vesicles of around 100 nm in diameter that are secreted by most cells and contain various bioactive molecules reflecting their cellular origin and mediate intercellular communication. Studies of these exosomal features in tumor pathogenesis have led to the development of therapeutic and diagnostic approaches using exosomes for cancer therapy. Exosomes have many advantages for conveying therapeutic agents such as small interfering RNAs, microRNAs, membrane-associated proteins, and chemotherapeutic compounds; thus, they are considered a prime candidate as a delivery tool for cancer treatment. Since exosomes also provide an optimal microenvironment for the effective function of immunomodulatory factors, exosomes harboring bioactive molecules have been bioengineered as cancer immunotherapies that can effectively activate each stage of the cancer immunity cycle to successfully elicit cancer-specific immunity. This review discusses the advantages of exosomes for treating cancer and the challenges that must be overcome for their successful clinical development.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0